EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens

Farokh Dotiwala iD, Arun K Upadhyay iD

Vaccines · 12.10.2023 · 11 (10) · 1585

DOI: 10.3390/vaccines11101585 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 12.10.2023. Verfasst von Farokh Dotiwala und 1 weiteren Autor:innen. Beteiligte Einrichtung: Ocugen Inc., 11 Great Valley Parkway, Malvern, PA 19355, USA. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 224 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ocugen Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inducing humoral and cytotoxic mucosal immunity at the sites of pathogen entry has the potential to prevent the infection from getting established. This is different from systemic vaccination, which protects against the development of systemic symptoms. The field of mucosal vaccination has seen fewer technological advances compared to nucleic acid and subunit vaccine advances for injectable vaccine platforms. The advent of the next-generation adenoviral vectors has given a boost to mucosal vaccine research. Basic research into the mechanisms regulating innate and adaptive mucosal immunity and the discovery of effective and safe mucosal vaccine adjuvants will continue to improve mucosal vaccine design. The results from clinical trials of inhaled COVID-19 vaccines demonstrate their ability to induce the proliferation of cytotoxic T cells and the production of secreted IgA and IgG antibodies locally, unlike intramuscular vaccinations. However, these mucosal vaccines induce systemic immune responses at par with systemic vaccinations. This review summarizes the function of the respiratory mucosa-associated lymphoid tissue and the advantages that the adenoviral vectors provide as inhaled vaccine platforms.

Schlagwörter

Stichwörter der Autor:innen

COVID-19SARS-CoV-2adenovirusinfluenzainhaled vaccinesmRNAmucosa-associated lymphoid tissuemucosal immunityrespiratory infections

Autor:innen und Institutionen

  • Ocugen Inc., 11 Great Valley Parkway, Malvern, PA 19355, USA.

ORCID-Profile: Farokh Dotiwala, Arun K Upadhyay

Förderung

  • Ocugen Inc.

Zitieren

APA

Dotiwala, F., & Upadhyay, A. K. (2023). Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens. Vaccines, 11(10), 1585. https://doi.org/10.3390/vaccines11101585

Vancouver

Dotiwala F, Upadhyay AK. Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens. Vaccines. 2023;11(10):1585. doi:10.3390/vaccines11101585

BibTeX
@article{Dotiwala2023,
  author = {Dotiwala, Farokh and Upadhyay, Arun K},
  title = {Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens},
  journal = {Vaccines},
  year = {2023},
  volume = {11},
  number = {10},
  pages = {1585},
  doi = {10.3390/vaccines11101585}
}
Kostenlos starten →